The FTC and 13 states are suing to stop Covetrus buying MWI. Your supply invoices are the reason

Business

The FTC and 13 states are suing to stop Covetrus buying MWI. Your supply invoices are the reason

On 13 November the Federal Trade Commission sued to block the $3.5 billion merger of the two largest US veterinary distributors. The complaint is built on the price war practices have been quietly benefiting from.

viggoVet Team

viggoVet Team

viggoVet Editorial

November 20, 20269 min read

Summarize with

If you have ever logged in to compare what two distributors want for the same box of vaccines, you are part of the Federal Trade Commission's case.

On November 13, 2026, the FTC sued to block Covetrus's $3.5 billion acquisition of MWI Animal Health from Cencora. Thirteen state attorneys general joined the complaint, filed in the US District Court for the Southern District of New York. The Commission voted 2 to 0 to authorize staff to seek a permanent injunction.

The allegation is simple. Covetrus and MWI are, according to the FTC, the two largest suppliers to US veterinary clinics, and each other's closest competitor. Merge them, the agency says, and clinics pay more, service gets worse, and the cost lands on pet owners.

What was on the table

The deal was announced in February. Covetrus, which is owned by the private equity firms Clayton, Dubilier & Rice and TPG, agreed to combine with MWI. Under the terms reported by dvm360 and the Philadelphia Inquirer, Cencora would receive $1.25 billion in cash up front, $800 million in preferred equity and $1.45 billion in common equity, and keep a stake of about 34% in the combined company.

At the time, Covetrus president and CEO Ben Wolin described it this way: "This combination is about making animal health care more affordable and accessible." Cencora CEO Robert Mauch said the transaction "positions MWI for success with a partner strategically focused on and dedicated to animal health."

Regulators started asking questions over the summer. By early August, Bloomberg reported (as relayed by Reuters and Vet Candy) that the FTC was requesting information from veterinary customers and competitors. Three months later it sued.

The case in the FTC's own words

The FTC's complaint describes two companies that supply pharmaceuticals, vaccines, "white goods," surgical supplies and thousands of other products to clinics, each with a national network of distribution centers and discounts and rebates smaller rivals cannot match.

Then it describes the competition between them. When MWI priced aggressively, the FTC says, Covetrus responded by cutting its own prices and offering rebates through its VetSuite program. Vetcove, the online price-comparison platform, made that rivalry sharper by letting veterinarians play one distributor's pricing against the other. The agency's summary of the result: years of competition that amounted to an all-out price war.

"This transaction will reduce competition in an already concentrated market," said Daniel Guarnera, director of the FTC's Bureau of Competition. "Covetrus wants to eliminate its closest competitor rather than compete for veterinary clinic customers."

The FTC argues two markets are affected: distribution to veterinary clinics, and distribution to large corporate accounts. It says specialty distributors, manufacturers and retailers do not meaningfully constrain the big two, that entry is hard, and that the markets are concentrated enough for the deal to be presumed unlawful under current case law and the 2023 merger guidelines. The public release does not give market share figures.

The states that joined are Arizona, Arkansas, California, Colorado, Maine, Michigan, Minnesota, Nebraska, New York, North Carolina, Ohio, Oregon and Texas, a mix the Inquirer described as bipartisan. New York Attorney General Letitia James put the consumer argument plainly: "A trip to the vet should never break the bank. Pet owners are already paying enormous prices for care, and this merger would threaten to drive costs even higher."

Covetrus's answer

Covetrus said it will fight. In a statement the same day, it said the lawsuit "does not reflect an accurate understanding of how veterinarians actually buy the products they need" and that the FTC's case "relies on a narrow and outdated view of the market."

Its argument is that buying has changed. "Clinics today choose freely from numerous manufacturers and distributors to meet their needs," the company said. Covetrus says online veterinary marketplaces are used by more than 60% of US practices and give access to more than 40 distributors and thousands of manufacturers.

That is the real disagreement, and it is a factual one a court can test. The FTC reads the marketplaces as the tool that made Covetrus and MWI compete harder against each other. Covetrus reads them as proof that the two are just two options among dozens.

| | FTC and states | Covetrus |
|---|---|---|
| Who competes for clinic business | Mainly Covetrus and MWI, each other's closest rival | More than 40 distributors plus manufacturers |
| Role of online marketplaces | Intensified the price war between the two | Show clinics already choose freely |
| Likely effect of the deal | Higher costs for clinics, worse service, higher prices for owners | More affordable, accessible animal health care |
| What they want | A permanent injunction blocking the deal | To defend the deal in court |

Sources: FTC release and dvm360, November 13, 2026; Philadelphia Inquirer, November 16, 2026.

Why practice owners should care either way

Distribution is not glamorous, but almost everything a companion animal practice dispenses or uses passes through it. Drugs, vaccines, consumables and diagnostics run through a distributor, and the price you pay is set partly by list, partly by rebate programs and partly by whether you can credibly take your business elsewhere.

That last part is what the FTC is defending. If you have used a comparison platform, split orders, or told a rep you were seeing a better price somewhere else, you have been using exactly the leverage the agency says this deal would remove. Independent practices without corporate purchasing contracts are likely to feel any change in that leverage first.

It also helps to separate what is decided from what is not. Nothing has changed in your supply chain yet. The two companies remain separate, and a court will now decide whether the deal can proceed.

What it means for your practice

  • Keep comparing prices. The FTC's own case says that shopping between distributors is what kept prices down. That remains true whether or not the deal survives.
  • Look at your rebate terms. Rebate and loyalty programs are a big part of what the FTC describes. Know what yours are worth and what they lock you into.
  • Avoid single-source dependence where you can. Having a working account with more than one supplier costs a little administrative time and keeps your options real.
  • Watch the court docket, not the headlines. The complaint was filed under seal, according to the Inquirer. The redacted version, when released, will likely contain the market share numbers the press release left out.

What we do not know yet

The schedule for the case, whether Covetrus and Cencora will push ahead or restructure, and how large the overlap really is in the numbers the FTC has not yet made public. Cencora had told investors earlier this year that its fiscal 2026 outlook did not assume the deal would close before its fiscal year ended in September. It now has a federal lawsuit standing in the way of a close at all.

References

  1. Federal Trade Commission, (2026). FTC sues to block veterinary supplies distributor Covetrus's $3.5 billion acquisition of rival MWI,Link
  2. Caitlin McCafferty, (2026). FTC sues to block Covetrus' merger with MWI Animal Health,Link
  3. Andrew Seidman, (2026). Federal Trade Commission sues to block acquisition of Cencora's MWI Animal Health,Link
  4. Vet Candy, (2026). FTC Takes a Closer Look at Proposed Cencora-Covetrus Merger,Link
  5. Abi Bautista-Alejandre, (2026). Covetrus and MWI Animal Health agree to merge in $3.5 billion deal,Link